Introduction: Whole body imaging of 18F-fluoroestradiol (FES) uptake combined with positron emission tomography (PET) has been applied for diagnosis and prediction of therapy response in estrogen receptor (ER) positive breast cancer patients. A maximal standardized uptake value (SUVmax) of 1.5 has previously been defined as the optimal threshold for FES uptake to differentiate between ER-positive and negative tumor lesions. FES uptake in healthy tissue differs per anatomic site and can be influenced by extrinsic factors. Previous FES PET studies have suggested that radiotherapy (RTx) may cause heterogeneous enhanced uptake in lungs. The cause of this uptake has not been elucidated yet. This is an exploratory study to evaluate whether patien...
Purpose Whereas anti-oestrogen therapy is widely applied to treat oestrogen receptor (ER) positive b...
Recent advances with specific PET tracer ligands, for example prostate-specific membrane antigen (PS...
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However, knowledg...
Introduction: Whole body imaging of 18F-fluoroestradiol (FES) uptake combined with positron emission...
RATIONALE: The use of 16α-[18F]fluoro-17β-estradiol (FES) positron emission tomography (PET) in clin...
RATIONALE: The use of 16α-[18F]fluoro-17β-estradiol (FES) positron emission tomography (PET) in clin...
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individ...
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individ...
16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is an estrogen receptor (ER)-specific PET tracer w...
16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is an estrogen receptor (ER)-specific PET tracer w...
Breast cancer is one of the most commonly diagnosed cancers and the leading cause of cancer mortalit...
PURPOSE: The aim of the study was to determine the correlation between 16\u3b1-18F-fluoro- 17\u3b2-...
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However, knowledg...
Purpose Whereas anti-oestrogen therapy is widely applied to treat oestrogen receptor (ER) positive b...
Recent advances with specific PET tracer ligands, for example prostate-specific membrane antigen (PS...
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However, knowledg...
Introduction: Whole body imaging of 18F-fluoroestradiol (FES) uptake combined with positron emission...
RATIONALE: The use of 16α-[18F]fluoro-17β-estradiol (FES) positron emission tomography (PET) in clin...
RATIONALE: The use of 16α-[18F]fluoro-17β-estradiol (FES) positron emission tomography (PET) in clin...
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individ...
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individ...
16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is an estrogen receptor (ER)-specific PET tracer w...
16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is an estrogen receptor (ER)-specific PET tracer w...
Breast cancer is one of the most commonly diagnosed cancers and the leading cause of cancer mortalit...
PURPOSE: The aim of the study was to determine the correlation between 16\u3b1-18F-fluoro- 17\u3b2-...
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However, knowledg...
Purpose Whereas anti-oestrogen therapy is widely applied to treat oestrogen receptor (ER) positive b...
Recent advances with specific PET tracer ligands, for example prostate-specific membrane antigen (PS...
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However, knowledg...